TAS0728 is an orally available, HER2-selective covalent inhibitor with high specificity for HER2 over wild-type EGFR and has exhibited potent inhibitory activity for both overexpressed/amplified HER2 and mutated HER2 in cancer cells [2]. The gene discussed is EGFR; the disease is cancer.